☰

Peter M. Haverty, Ph.D. - Publications

Affiliations: 
2005 Boston University, Boston, MA, United States 
Area:
Biostatistics Biology, Molecular Biology
Tree Info Similar researchers PubMed Report error

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Raisner R, Bainer R, Haverty PM, Benedetti KL, Gascoigne KE. Super-enhancer acquisition drives oncogene expression in triple negative breast cancer. Plos One. 15: e0235343. PMID 32584896 DOI: 10.1371/Journal.Pone.0235343  0.37
2019 Kong Y, Rose CM, Cass AA, Williams AG, Darwish M, Lianoglou S, Haverty PM, Tong AJ, Blanchette C, Albert ML, Mellman I, Bourgon R, Greally J, Jhunjhunwala S, Chen-Harris H. Transposable element expression in tumors is associated with immune infiltration and increased antigenicity. Nature Communications. 10: 5228. PMID 31745090 DOI: 10.1038/S41467-019-13035-2  0.349
2019 Fortin JP, Tan J, Gascoigne KE, Haverty PM, Forrest WF, Costa MR, Martin SE. Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens. Genome Biology. 20: 21. PMID 30683138 DOI: 10.1186/S13059-019-1621-7  0.321
2018 Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T, Khan Z, Mariathasan S, Daemen A, Reeder J, Haverty PM, Forrest WF, Brauer M, Mellman I, Albert ML. Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. Proceedings of the National Academy of Sciences of the United States of America. PMID 30463956 DOI: 10.1073/Pnas.1804506115  0.37
2018 Raisner R, Kharbanda S, Jin L, Jeng E, Chan E, Merchant M, Haverty PM, Bainer R, Cheung T, Arnott D, Flynn EM, Romero FA, Magnuson S, Gascoigne KE. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. Cell Reports. 24: 1722-1729. PMID 30110629 DOI: 10.1016/J.Celrep.2018.07.041  0.33
2018 Wagle MC, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, Moffat J, Merchant M, Huw L, Wongchenko M, Okrah K, Srinivasan S, Mounir Z, Sumiyoshi T, Haverty PM, et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. Npj Precision Oncology. 2: 7. PMID 29872725 DOI: 10.1038/s41698-018-0051-4  0.306
2017 Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, Cheng J, Hunsaker T, Shao L, Wang SJ, Wagle MC, Lin E, Haverty PM, Shahidi-Latham S, Ngu H, et al. Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. Plos One. 12: e0185862. PMID 28982154 DOI: 10.1371/Journal.Pone.0185862  0.315
2016 Sahu N, Dela Cruz D, Gao M, Sandoval W, Haverty PM, Liu J, Stephan JP, Haley B, Classon M, Hatzivassiliou G, Settleman J. Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis. Cell Metabolism. PMID 27618686 DOI: 10.1016/J.Cmet.2016.08.008  0.324
2016 Haverty PM, Lin E, Tan J, Yu Y, Lam B, Lianoglou S, Neve RM, Martin S, Settleman J, Yauch RL, Bourgon R. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature. 533: 333-7. PMID 27193678 DOI: 10.1038/Nature17987  0.334
2016 Wagle M, Klijn C, Liu B, Mahajan S, Haverty P, Moffat J, Merchant M, Yauch B, Hampton G, Amler L, Lackner M, Huang SA. Abstract 417: A novel predictive biomarker model for MEK sensitivity Cancer Research. 76: 417-417. DOI: 10.1158/1538-7445.Am2016-417  0.336
2015 Vartanian S, Ma TP, Lee J, Haverty PM, Kirkpatrick DS, Yu K, Stokoe D. Application of mass spectrometry profiling to establish brusatol as an inhibitor of global protein synthesis. Molecular & Cellular Proteomics : McP. PMID 26711467 DOI: 10.1074/Mcp.M115.055509  0.358
2015 Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, ... ... Haverty PM, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research : Bcr. 17: 59. PMID 25902869 DOI: 10.1186/S13058-015-0564-5  0.376
2015 Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 27: 327-41. PMID 25759019 DOI: 10.1016/J.Ccell.2015.02.001  0.328
2015 Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, Pau G, Reeder J, Cao Y, Mukhyala K, Selvaraj SK, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nature Biotechnology. 33: 306-12. PMID 25485619 DOI: 10.1038/Nbt.3080  0.439
2015 Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, ... ... Haverty PM, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nature Genetics. 47: 13-21. PMID 25401301 DOI: 10.1038/Ng.3146  0.393
2015 Mahrus S, DuPree K, Kowanetz K, Tan J, Tremayne J, Jakubiak D, Haverty P, Zhu Y, Peale F, Blackwood E, Bourgon R, Yauch R, Lackner M, Evangelista M. Abstract 944: Development of predictive and pharmacodynamic biomarker strategies for GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine Cancer Research. 75: 944-944. DOI: 10.1158/1538-7445.Am2015-944  0.377
2014 Mayba O, Gilbert HN, Liu J, Haverty PM, Jhunjhunwala S, Jiang Z, Watanabe C, Zhang Z. MBASED: allele-specific expression detection in cancer tissues and cell lines. Genome Biology. 15: 405. PMID 25315065 DOI: 10.1186/S13059-014-0405-3  0.414
2014 Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, et al. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. The Journal of Pathology. 234: 502-13. PMID 25074413 DOI: 10.1002/Path.4412  0.336
2014 Liu J, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, Durinck S, Chen YJ, Klijn C, Jhunjhunwala S, Lawrence M, Liu H, Wan Y, Chopra V, Yaylaoglu MB, et al. Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer. Nature Communications. 5: 3830. PMID 24807215 DOI: 10.1038/Ncomms4830  0.376
2014 Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, Davis D, Stokoe D, Settleman J, de Sauvage FJ, Neve RM. Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. Cancer Research. 74: 3114-26. PMID 24755469 DOI: 10.1158/0008-5472.Can-13-2683  0.439
2013 Shames DS, Elkins K, Walter K, Holcomb T, Du P, Mohl D, Xiao Y, Pham T, Haverty PM, Liederer B, Liang X, Yauch RL, O'Brien T, Bourgon R, Koeppen H, et al. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6912-23. PMID 24097869 DOI: 10.1158/1078-0432.Ccr-13-1186  0.374
2013 Hwang TH, Atluri G, Kuang R, Kumar V, Starr T, Silverstein KA, Haverty PM, Zhang Z, Liu J. Large-scale integrative network-based analysis identifies common pathways disrupted by copy number alterations across cancers. Bmc Genomics. 14: 440. PMID 23822816 DOI: 10.1186/1471-2164-14-440  0.386
2013 Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, Harris AL, Friedman LS, Belvin M, Middleton MR, Blackwood EM, et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Journal of the National Cancer Institute. 105: 606-7. PMID 23535073 DOI: 10.1093/Jnci/Djt054  0.344
2012 Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6771-83. PMID 23136191 DOI: 10.1158/1078-0432.Ccr-12-2347  0.378
2012 Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, Vartanian S, Walter K, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Research. 22: 2315-27. PMID 23033341 DOI: 10.1101/Gr.140988.112  0.385
2012 Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, ... Haverty PM, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genetics. 44: 1111-6. PMID 22941189 DOI: 10.1038/Ng.2405  0.43
2012 Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F, ... ... Haverty PM, et al. Recurrent R-spondin fusions in colon cancer. Nature. 488: 660-4. PMID 22895193 DOI: 10.1038/Nature11282  0.426
2012 Wallin JJ, Guan J, Edgar KA, Zhou W, Francis R, Torres AC, Haverty PM, Eastham-Anderson J, Arena S, Bardelli A, Griffin S, Goodall JE, Grimshaw KM, Hoeflich KP, Torrance C, et al. Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. Plos One. 7: e36402. PMID 22570710 DOI: 10.1371/Journal.Pone.0036402  0.332
2012 Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Molecular Cancer Therapeutics. 11: 1143-54. PMID 22402123 DOI: 10.1158/1535-7163.Mct-11-1010  0.311
2012 O'Brien CL, Spoerke J, Lackner M, Sproul S, Haverty P, Hampton G. Abstract 5609: Mechanisms of acquired resistance to selective PI3K inhibitors in breast cancer cell lines Cancer Research. 72: 5609-5609. DOI: 10.1158/1538-7445.Am2012-5609  0.336
2012 Ong C, Jubb A, Haverty P, Zhou W, Lyle K, Harris A, Belvin M, Friedman L, Koeppen H, Hoeflich KP. Abstract 4004: P21-activated kinases (PAKs) are novel therapeutic targets in human breast cancer Cancer Research. 72: 4004-4004. DOI: 10.1158/1538-7445.Am2012-4004  0.359
2012 Ong CC, Jubb AM, Haverty PM, Zhou W, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. Abstract B8: Targeting p21-activated kinases in human lung cancer Clinical Cancer Research. 18: B8-B8. DOI: 10.1158/1078-0432.12Aacriaslc-B8  0.339
2011 Lee-Hoeflich ST, Pham TQ, Dowbenko D, Munroe X, Lee J, Li L, Zhou W, Haverty PM, Pujara K, Stinson J, Chan SM, Eastham-Anderson J, Pandita A, Seshagiri S, Hoeflich KP, et al. PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discovery. 1: 326-37. PMID 22586611 DOI: 10.1158/2159-8290.Cd-11-0062  0.338
2011 Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2: 491-6. PMID 21653999 DOI: 10.18632/Oncotarget.271  0.329
2011 Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H, Hoeflich KP. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 7177-82. PMID 21482786 DOI: 10.1073/Pnas.1103350108  0.357
2011 Jubb AM, Hoeflich KP, Haverty PM, Wang J, Koeppen H. Ascl2 and 11p15.5 amplification in colorectal cancer. Gut. 60: 1606-7; author reply. PMID 21106550 DOI: 10.1136/Gut.2010.231746  0.326
2010 Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 466: 869-73. PMID 20668451 DOI: 10.1038/Nature09208  0.38
2010 Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, Ha C, Johnson S, Kennemer MI, Mohan S, Nazarenko I, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 465: 473-7. PMID 20505728 DOI: 10.1038/Nature09004  0.391
2009 Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4147-56. PMID 19509167 DOI: 10.1158/1078-0432.Ccr-08-2814  0.308
2009 Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. Bmc Medical Genomics. 2: 21. PMID 19419571 DOI: 10.1186/1755-8794-2-21  0.387
2009 Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, Chant J, Stokoe D, Lackner MR, Cavet G. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Molecular Cancer Research : McR. 7: 511-22. PMID 19372580 DOI: 10.1158/1541-7786.Mcr-08-0107  0.378
2008 Haverty PM, Fridlyand J, Li L, Getz G, Beroukhim R, Lohr S, Wu TD, Cavet G, Zhang Z, Chant J. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes, Chromosomes & Cancer. 47: 530-42. PMID 18335499 DOI: 10.1002/Gcc.20558  0.413
2007 Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, Sebisanovic D, Stinson J, Forrest WF, Bazan JF, Seshagiri S, Zhang Z. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Research. 67: 465-73. PMID 17234753 DOI: 10.1158/0008-5472.Can-06-1736  0.356
2005 Yu L, Haverty PM, Mariani J, Wang Y, Shen HY, Schwarzschild MA, Weng Z, Chen JF. Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum. Physiological Genomics. 23: 89-102. PMID 16046619 DOI: 10.1152/Physiolgenomics.00068.2005  0.544
2005 Haverty PM, Weng Z, Hansen U. Transcriptional Regulatory Networks Activated by PI3K and ERK Transduced Growth Signals in Human Glioblastoma Cells Journal of Computer Science and Technology. 20: 439-445. DOI: 10.1007/S11390-005-0439-9  0.565
2004 Haverty PM, Hsiao LL, Gullans SR, Hansen U, Weng Z. Limited agreement among three global gene expression methods highlights the requirement for non-global validation. Bioinformatics (Oxford, England). 20: 3431-41. PMID 15256402 DOI: 10.1093/Bioinformatics/Bth421  0.518
2004 Fu Y, Frith MC, Haverty PM, Weng Z. MotifViz: an analysis and visualization tool for motif discovery. Nucleic Acids Research. 32: W420-3. PMID 15215422 DOI: 10.1093/Nar/Gkh426  0.659
2004 Haverty PM, Frith MC, Weng Z. CARRIE web service: automated transcriptional regulatory network inference and interactive analysis. Nucleic Acids Research. 32: W213-6. PMID 15215383 DOI: 10.1093/Nar/Gkh402  0.647
2004 Haverty PM, Weng Z. CisML: an XML-based format for sequence motif detection software. Bioinformatics (Oxford, England). 20: 1815-7. PMID 15001475 DOI: 10.1093/Bioinformatics/Bth162  0.497
2004 Haverty PM, Hansen U, Weng Z. Computational inference of transcriptional regulatory networks from expression profiling and transcription factor binding site identification. Nucleic Acids Research. 32: 179-88. PMID 14704355 DOI: 10.1093/Nar/Gkh183  0.576
2002 Haverty PM, Weng Z, Best NL, Auerbach KR, Hsiao LL, Jensen RV, Gullans SR. HugeIndex: a database with visualization tools for high-density oligonucleotide array data from normal human tissues. Nucleic Acids Research. 30: 214-7. PMID 11752297 DOI: 10.1093/Nar/30.1.214  0.548
2001 Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon W, Lee KF, Clark KE, Haverty P, Weng Z, Mutter GL, Frosch MP, MacDonald ME, Milford EL, et al. A compendium of gene expression in normal human tissues. Physiological Genomics. 7: 97-104. PMID 11773596 DOI: 10.1152/Physiolgenomics.00040.2001  0.53
Show low-probability matches.